Fundamental Neuro |
Fundamental Neuro |
Unfinished |
2022-11-20 |
megangodfrey97 |
20 |
0 |
edit |
|
CNS |
1.6 |
Unfinished |
2022-11-20 |
megangodfrey97 |
38 |
0 |
edit |
|
Top 200A |
generic-brand name |
Pharmacology |
2023-03-07 |
megangodfrey97 |
100 |
0 |
edit |
|
Top 200-A P2 |
MOA |
Unfinished |
2023-12-30 |
megangodfrey97 |
100 |
0 |
edit |
|
1.9 |
lecture 1 |
Unfinished |
2023-01-25 |
megangodfrey97 |
44 |
0 |
edit |
|
1.10 |
Drugs |
Pharmacology |
2023-02-23 |
megangodfrey97 |
80 |
0 |
edit |
|
1.11 |
hypothalamic and pituitary hormones |
Pharmacology |
2023-02-23 |
megangodfrey97 |
73 |
0 |
edit |
|
1.11 |
Corticosteroids |
Pharmacology |
2023-02-23 |
megangodfrey97 |
36 |
0 |
edit |
|
1.11 |
Calcium Hormones |
Pharmacology |
2023-02-26 |
megangodfrey97 |
49 |
0 |
edit |
|
1.11 |
Thyroid Hormones |
Pharmacology |
2023-02-26 |
megangodfrey97 |
32 |
0 |
edit |
|
1.11 |
Androgens |
Pharmacology |
2023-02-26 |
megangodfrey97 |
43 |
0 |
edit |
|
1.11 |
Uterine Cycle/Menstrual Cycle |
Pharmacology |
2023-02-26 |
megangodfrey97 |
21 |
0 |
edit |
|
1.11 |
Estrogen |
Pharmacology |
2023-02-26 |
megangodfrey97 |
27 |
0 |
edit |
|
1.11 |
progestins |
Pharmacology |
2023-02-27 |
megangodfrey97 |
26 |
0 |
edit |
|
1.11 |
Hormonal Contraceptives |
Pharmacology |
2023-02-28 |
megangodfrey97 |
61 |
0 |
edit |
|
1.11 |
Hormone Replacement Therapy |
Pharmacology |
2023-02-28 |
megangodfrey97 |
18 |
0 |
edit |
|
Top200 B |
Drugs |
Unfinished |
2024-04-20 |
megangodfrey97 |
99 |
1 |
edit |
|
2.3 Brand Names |
2.3 Brand Names |
Unfinished |
2023-10-04 |
megangodfrey97 |
92 |
0 |
edit |
|
2.3 ADRs |
2.3 ADRs |
Unfinished |
2023-10-04 |
megangodfrey97 |
37 |
0 |
edit |
|
2.5-nutrition |
2.5-nutrition |
Unfinished |
2023-11-10 |
megangodfrey97 |
35 |
0 |
edit |
|
Top 200-A P2 |
Schedule |
Unfinished |
2023-12-29 |
megangodfrey97 |
22 |
0 |
edit |
|
Top 200-A P2 |
Categories |
Unfinished |
2023-12-30 |
megangodfrey97 |
100 |
0 |
edit |
|
Top 200-A P2 |
Indications |
Unfinished |
2023-12-30 |
megangodfrey97 |
100 |
0 |
edit |
|
2.8 |
Principles of ID |
Unfinished |
2024-01-06 |
megangodfrey97 |
47 |
0 |
edit |
|
2.9 Drugs |
2.9 Drugs indications |
Unfinished |
2024-01-21 |
megangodfrey97 |
33 |
0 |
edit |
|
2.9 Drugs |
2.9 Drugs MOA |
Unfinished |
2024-01-21 |
megangodfrey97 |
4 |
0 |
edit |
|
2.10 |
Dosing |
Unfinished |
2024-02-04 |
megangodfrey97 |
24 |
0 |
edit |
|
2.11 drugs |
Brand/generic |
Unfinished |
2024-02-28 |
megangodfrey97 |
52 |
0 |
edit |
|
2.11 |
Introduction material |
Unfinished |
2024-02-28 |
megangodfrey97 |
77 |
0 |
edit |
|
2.11 |
Bipolar Disorder |
Unfinished |
2024-02-28 |
megangodfrey97 |
25 |
0 |
edit |
|
2.11 |
Asthma |
Unfinished |
2024-02-28 |
megangodfrey97 |
48 |
0 |
edit |
|
2.11 |
Allergic Rhinitis |
Unfinished |
2024-02-28 |
megangodfrey97 |
19 |
0 |
edit |
|
2.11 |
Cystic Fibrosis |
Unfinished |
2024-02-28 |
megangodfrey97 |
40 |
0 |
edit |
|
2.11 |
Schizophrenia |
Unfinished |
2024-02-28 |
megangodfrey97 |
92 |
0 |
edit |
|
2.11 |
Depression |
Unfinished |
2024-02-28 |
megangodfrey97 |
59 |
0 |
edit |
|
2.11 |
Substance Use |
Unfinished |
2024-02-28 |
megangodfrey97 |
70 |
0 |
edit |
|
2.11 |
ADHD/Eating Disorders |
Unfinished |
2024-02-28 |
megangodfrey97 |
53 |
0 |
edit |
|
2.13 |
constipation, diarrhea, IBS drug classes |
Unfinished |
2024-03-31 |
megangodfrey97 |
27 |
0 |
edit |
|
2.13 |
constipation, diarrhea, IBS Drug/MOA |
Unfinished |
2024-03-31 |
megangodfrey97 |
59 |
0 |
edit |
|
2.13 |
GERD |
Unfinished |
2024-04-01 |
megangodfrey97 |
53 |
0 |
edit |
|
2.13 |
Peptic Ulcer Disease and GI bleed |
Unfinished |
2024-04-01 |
megangodfrey97 |
61 |
0 |
edit |
|
2.13 |
pancreatitis |
Unfinished |
2024-04-02 |
megangodfrey97 |
61 |
0 |
edit |
|
2.13 |
N/V |
Unfinished |
2024-04-02 |
megangodfrey97 |
76 |
0 |
edit |
|
2.13 |
Liver Disease |
Unfinished |
2024-04-02 |
megangodfrey97 |
90 |
0 |
edit |
|
2.13 |
Inflammatory bowel disease |
Unfinished |
2024-04-02 |
megangodfrey97 |
112 |
0 |
edit |
|
2.13 |
advanced cardiovascular life support |
Unfinished |
2024-04-02 |
megangodfrey97 |
56 |
0 |
edit |
|
2.13 |
critical care |
Unfinished |
2024-04-03 |
megangodfrey97 |
73 |
0 |
edit |
|
2.13 |
shock syndrome |
Unfinished |
2024-04-03 |
megangodfrey97 |
35 |
0 |
edit |
|
Top200B |
Contraindications |
Unfinished |
2024-04-22 |
megangodfrey97 |
71 |
0 |
edit |
|
3.15 |
pain management |
Unfinished |
2024-05-03 |
megangodfrey97 |
25 |
0 |
edit |
|
3.15 |
fibromyalgia/chronic pain |
Unfinished |
2024-05-02 |
megangodfrey97 |
80 |
0 |
edit |
|
2.15 |
Parkinson's |
Unfinished |
2024-05-02 |
megangodfrey97 |
96 |
0 |
edit |
|
2.15 |
pain dosage form |
Unfinished |
2024-05-03 |
megangodfrey97 |
32 |
0 |
edit |
|
2.15 |
pain-brand/generic |
Unfinished |
2024-05-03 |
megangodfrey97 |
15 |
0 |
edit |
|
2.15 |
pain-organ dysfunction |
Unfinished |
2024-05-03 |
megangodfrey97 |
13 |
0 |
edit |
|